Don't Sweat Duolingo Stock's June Doldrums
The shares of language learning platform Duolingo Inc (NASDAQ:DUOL) are down 2.7% at $411.54 at last glance, looking to extend their recent slide. hung around its May 14 record high of $544.93 for a few weeks before beginning a sharp descent lower, marking only three positive days since June 6.
On the side of the bulls, however, DUOL is still up 26.9% in 2025, and currently flashing a historically bullish signal. Per Schaeffer's Senior Quantitative Analyst Rocky White, the recent pullback has Duolingo stock within striking distance of its 80-day moving average.
More specifically, the stock is within 0.75 of the trendline's 20-day average true range (ATR) after spending at least 80% of the last 10 days and 80% of the last two months above it. Within these parameters, six other signals occurred in the past three years. DUOL was higher one month later 67% of the time after those instances, averaging a large 15.7% gain. A move of similar magnitude would have the shares back up above $476, recovering a good portion of its recent losses.
Also in the stock's favor, its 14-day relative strength index (RSI) of 13.2 sits firmly in "oversold" territory, pointing to a potential short-term bounce. An unwinding of pessimism amongst options traders could provide tailwinds as well, per DUOL's 50-day put/call volume ratio of 1.83 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which ranks higher than 98% of readings from the past year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright isn't backing off Summit Therapeutics (NASDAQ: SMMT). On June 2, the firm reaffirmed its Buy rating and maintained a $44 price target, more than double the current $18.21 share price. Analyst targets for the stock now range between $30 and $44.15, with a strong Buy consensus across the board. At a market cap of $13.5 billion, Summit has the attention of the street. The reason is Ivonescimab. It's Summit's checkpoint inhibitor drug, and Wainwright believes it could end up setting a new standard in treating solid tumors. They focused on recent HARMONi trial results. It's not statistically significant on overall survival, but strong enough on other metrics to keep hopes high. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. In particular, they pointed to ivonescimab's progression-free survival hazard ratio of 0.52 when paired with chemo. That compares favorably to the 0.8 seen with Merck's KEYTRUDA in the KEYNOTE-789 trial for the same cancer type—TKI-resistant, EGFR-mutated non-small cell lung cancer. Despite a 30% drop in the stock in the week prior to the price target update, triggered by disappointment over survival stats, Wainwright argued the market is missing the point. No competing drug has hit statistical significance either. They also noted Summit's beta sits at -0.95, which means it tends to move opposite the market, which is something investors might want to consider. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright isn't backing off Summit Therapeutics (NASDAQ: SMMT). On June 2, the firm reaffirmed its Buy rating and maintained a $44 price target, more than double the current $18.21 share price. Analyst targets for the stock now range between $30 and $44.15, with a strong Buy consensus across the board. At a market cap of $13.5 billion, Summit has the attention of the street. The reason is Ivonescimab. It's Summit's checkpoint inhibitor drug, and Wainwright believes it could end up setting a new standard in treating solid tumors. They focused on recent HARMONi trial results. It's not statistically significant on overall survival, but strong enough on other metrics to keep hopes high. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. In particular, they pointed to ivonescimab's progression-free survival hazard ratio of 0.52 when paired with chemo. That compares favorably to the 0.8 seen with Merck's KEYTRUDA in the KEYNOTE-789 trial for the same cancer type—TKI-resistant, EGFR-mutated non-small cell lung cancer. Despite a 30% drop in the stock in the week prior to the price target update, triggered by disappointment over survival stats, Wainwright argued the market is missing the point. No competing drug has hit statistical significance either. They also noted Summit's beta sits at -0.95, which means it tends to move opposite the market, which is something investors might want to consider. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Why Symbotic Stock Soared Today
Symbotic stock rose today after Arete initiated coverage on the stock with a buy rating. Arete set a one-year price target of $50 per share on the stock, implying additional upside of 43%. Symbotic stock has posted strong gains in 2025, but its valuation profile suggests that shares may still have room to run. 10 stocks we like better than Symbotic › Symbotic (NASDAQ: SYM) stock closed out Wednesday's trading with big gains. The robotics and automation company's share price ended the daily session up 8.5%. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) was flat on the day, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) rose 0.3%. Symbotic stock's rally today was triggered by bullish coverage from an analyst. In a note published this morning, Arete Research initiated coverage on the company and gave its stock a buy rating. With the note it published today, Arete took a bullish stance on Symbotic and set a one-year price target of $50 per share for the stock. The coverage kicked off a wave of buying action, and the stock had been up as much as 10.7% earlier in the daily session. Even after today's gains, Arete's price target implies additional upside of roughly 43% and reflects confidence in continued growth opportunities for the company. Symbotic stock has been on an impressive hot streak in 2025, with excitement surrounding its artificial intelligence (AI) and robotics helping to push the company's share price up 47% year to date. The company now has a market capitalization of roughly $3.8 billion, but it's trading at a reasonable-looking 1.5 times this year's expected sales, and could still have room for substantial valuation upside. While the business posted a net loss of $21 million in its last reported quarter, the robotics specialist managed to grow revenue 40% year over year in the period. Revenue growth could be uneven going forward, but there seems to be a good chance that the company will be able to increase its margins as its business continues to scale. Before you buy stock in Symbotic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Symbotic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Symbotic. The Motley Fool has a disclosure policy. Why Symbotic Stock Soared Today was originally published by The Motley Fool
